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Comorbidity inﬂuences screening practice, treatment choice, quality of life, and survival. The presence of comorbidities and
medication use could place patients at greater risks of adverse eﬀects from certain interventions. We conducted a longitudinal
cohort study in the General Practice Research Database to better understand comorbidities and medication use in men with or
at risk of prostate cancer (CaP). Compared with men with similar age but no CaP, CaP patients had higher incidence of urinary
tract infection, impotence and breast disorder, and 2.6-fold higher all-cause mortality. Among men with elevated prostate-speciﬁc
antigen (PSA) but no CaP, the mortality rates were slightly lower, and fewer diﬀerences in comorbidities and medication use were
noted compared to men without elevated PSA. Many prevalent comorbidities and medications were consistent across groups and
are typical of an older male population. These real-world data are broadly applicable throughout the drug development cycle and
subsequent patient management.
1.Introduction
Prostate cancer (CaP) is the most common nonskin cancer
and the second or third leading cause of death from cancer
among men in the developed world [1]. In the UK, more
than 36,000 men are diagnosed with CaP each year, com-
prising a quarter of all cancers diagnosed in men. Although
approximately 10,000 men died from CaP in the UK in 2008,
survival rates for CaP patients have changed markedly over
the past 40 years. More than 75% of CaP patients current-
ly survive beyond ﬁve years, compared with less than a
third of the patients with ﬁve-year survival in the 1970s; the
diﬀerential is even greater in the ten-year survival experien-
ces now compared to 40 years ago [2]. Thus, the CaP patient
population is large. Moreover, in this large group, the burden
of disease from CaP is preponderantl in elderly men, with
men who are 70 years or older comprising more than half
the patient population in the UK.
Consequently, CaP patients often present for medical
care with advanced age-related comorbidities [3]. The num-
ber and types of patient comorbidities have informed treat-
ment choice for CaP in clinical practice, with less aggressive
treatment used as comorbidity increases [4–9]. Comorbidity
scores have been shown to predict outcomes ranging from
late urinary complications [10]t oo v e r a l ls u r v i v a l[ 11]
among men who have undergone radical prostatectomy.
Moreover, speciﬁc comorbidities, or a high number of com-
orbidities, have been used in some instances to exclude
patients from clinical trials due to concerns of increased risk
of adverse events [12]. Therefore, a thorough understanding
of the occurrence of comorbidities in CaP patients in a real-
world setting has important implications for drug develop-
ment, clinical practice, and patient management.
Whiletherehasbeenexcellentworktodatedocumenting
the impact of comorbidities on treatment decisions among2 Journal of Cancer Epidemiology
men with CaP, these studies have some limitations from the
perspective of clinical development of novel treatment or
preventive medicines. Many studies examined the existence
of the comorbidity only at the time of initial CaP diag-
nosis. There is sparse information that describes comorbid
illnesses that arise during the treatment phase of the disease.
Moreover, several studies restricted comorbid information
to scores for the intent of proﬁling the overall “risk” of
each patient, rather than examining speciﬁc comorbidities.
Additionally, only one study reported to date has compared
CaP patients to an age-similar non-CaP group. Quantiﬁca-
tion of speciﬁc concomitant diseases during a prevention
or treatment period in a population of patients that closely
mirror users of novel therapies and putting these rates in
context with rates from age-similar populations is useful.
Therefore, to complement the body of information from
previous studies, we conducted a longitudinal cohort study
in the General Practice Research Database (GPRD) among
men with CaP and compared speciﬁc comorbidities and
medications among these men to an age-, practice-, and
length of followup-matched set of controls. In addition to
prevalence of comorbidities at the time of initial cancer
diagnosis,weexaminedtheincidenceofmajorcomorbidities
during a follow-up period of approximately four years and
overall survival for the entire observation period in both
cases and controls. We further deﬁned a cohort of men at
risk for CaP, demonstrated by 2 or more elevations in PSA
level within 12 months, but without CaP, and matched this
high-risk group to a noncancer, non-PSA-elevated control
populationtoexplorebackgroundprevalence,incidence,and
medicationuseratesasaframeworkforbetterunderstanding
patients in one of our major on-going clinical development
programs.
2.Objectives
Theobjectiveofthisstudywastocomparetheprevalenceand
incidence of comorbidities and concomitant medication use
andoverallsurvivalinpatientswithCaPandinmenatriskof
CaP, deﬁned as having prostate-speciﬁc antigen (PSA) levels
>2.5ng/mL but without CaP, to men of the same age without
CaP and no elevated PSA. Comorbidities or newly occurring
events of speciﬁc interest included urinary tract infections
(UTI), impotence, breast disorders, hypertension, acute
coronary syndrome, myocardial infarction, angina pectoris,
stroke, congestive heart failure, cardiac arrhythmias, lower
extremity arterial occlusive disease, type II diabetes, and
hyperlipidemia, conditions selected for their relevance to the
age group and to reported events among men with or at risk
of CaP.
3.MaterialsandMethods
The study was a retrospective longitudinal comparative
cohort study of men in the GPRD, comprising data from
August 1, 1998 to July 31, 2008. We obtained institutional
review board (IRB) approval for conducting this study. The
GPRDisapopulation-basedelectronicmedicalrecordsdata-
base in the UK. Data are drawn from the computer systems
used by general practitioners (GPs) to maintain clinical
recordswithintheirpracticesandcontainallprimarycarere-
cords deemed relevant to patient care. Data quality is mon-
itored continuously by the UK Medicines and Healthcare
products Regulatory Agency (MHRA), and practices that fail
to maintain the required standards are removed from the
database. Currently, data are collected from 613 general pra-
ctices throughout the UK, providing information from 9.7
million patients with records in the system at any time
point and 4.5 million currently registered patients. Mean
follow-up is 6.6 years (median, 5.0 years) for currently re-
gistered patients.
3.1. Study Population. Among men ≥18 years of age in the
GPRD, we identiﬁed two cohorts of men, referred to as
“cases”: men with a diagnostic code of CaP who had no re-
cord of cancers other than CaP and nonmelanoma skin can-
cer and men with at least two elevated PSA results, deﬁned
as PSA > 2.5ng/mL, but no diagnosis of CaP. Given that
there is a continuum of CaP risk at all values of PSA and
no cutpoint of PSA with simultaneous high sensitivity and
high speciﬁcity for identifying CaP [13], PSA > 2.5ng/mL
was selected to be consistent with the inclusion criteria in a
major on-going clinical trial. A man with elevated PSA who
wentontohaveCaPwasincludedonlyintheCaPgroup.The
dateoftheﬁrstCaPdiagnosiswastheindexdateforeachCaP
patient, and the date when the ﬁrst elevated PSA result was
recorded was the index date for each man with elevated PSA
but no CaP. A second elevated PSA result must have been
recorded within 12 months after the index date to ensure a
true positive result, as patients may have had a false positive
reading or may have had elevated levels due to acute urinary
tract infection.
For each case, a control was selected among those who
had no diagnostic codes for CaP, no benign prostate condi-
tions,thatis,benignprostatichyperplasia(BPH)and/orpro-
statitis, and no elevated PSA result, but had at least one PSA
measurement throughout the 10-year observation period.
Cases could, however, have a diagnosis of prostatitis or BPH
at any time. Cases and controls were matched on age (±1
year when possible, up to ±5 years allowed), region of pra-
ctice, length of follow-up, and observation period (either
August 1, 1998 to July 31, 2003 or August 1, 2003 to July
31, 2008). Matching on region of practice was to ensure
similar socioeconomic factors, such as income and access to
health insurance or scored utilization of primary health care,
between cases and controls. Replacements were not allowed.
The index date for each control was the same as the index
date of his matched case.
We included only those men that had at least 12-month
history in the GPRD prior to the index date in order to ade-
quately assess prior occurrences of disease or event of inter-
est. Men must have had at least 3 months of follow-up post-
index date to be included in the postindex date analysis
of prevalent comorbidities and medications. No minimum
follow-upwasrequired foranalysisof incident comorbidities
and medications, which allowed inclusion of less healthy
(e.g., near terminal) CaP patients, resulting in a more gen-
eralizable CaP population. For medication use, we restrictedJournal of Cancer Epidemiology 3
our population to the subgroup of men with index dates
betweenAugust1,2003andJuly31,2008,inordertoprovide
a more up-to-date pattern for medication use.
Baseline characteristics included age at the index date,
region of practice (deﬁned as Eastern, Southern, Northern
London, and others), smoking status (deﬁned as never, cur-
rent,andpast),andPSAlevels.PSAlevelswerecategorizedas
≤2.5,2.51–10,and>10ng/mL.Theywerealsocategorizedby
the age-dependent UK cutoﬀ values of ≥3.0ng/mL for men
aged 50–59 years, ≥4.0ng/mL for men aged 60–69 years, and
>5.0ng/mLformenaged70yearsandover,asrecommended
by the Prostate Cancer Risk Management Programme [14].
3.2. Study Outcomes. Diseases and events of speciﬁc interest
included UTI, impotence, breast disorders, hypertension,
acutecoronarysyndrome,myocardialinfarction,anginapec-
toris, stroke, congestive heart failure, cardiac arrhythmias,
lower extremity arterial occlusive disease, type II diabetes,
and hyperlipidemia and were deﬁned according to the READ
and OXMIS Codes. General comorbidities were examined
amongtheentirecohortofmen,listedbytheMedDRAhigh-
level terms. Medications were assessed among a subgroup of
men in GPRD within the latter ﬁve years (i.e., index dates
between August 1, 2003 and July 31, 2008), listed by class
perBritishNationalFormulary(BNF)headerwithinthepro-
duct ﬁles. Patient mortality status (yes/no) was used for cal-
culating the all-cause mortality rates. Causes of death were
obtained for approximately 60% of patients in GPRD, those
who had consented to the linkage to the Oﬃce for National
Statistics (ONS) death data. The underlying causes of death
were recorded and described according to the International
Statistical Classiﬁcation of Diseases and Related Health Pro-
blems 10th Revision (ICD-10) [15]. Frequencies of more
than 2% for individual events and of more than 3% for sys-
tems of diseases were reported.
3.3. Statistical Analysis. We compared baseline characteris-
tics in the two case groups that were successfully control
matched to the cases we were unable to match. Within each
matched set, we compared baseline characteristics of each
case group to its respective control group.
For comorbidities of special interest, we examined the
prevalence during the 12 months prior to the index date
andthecumulativeincidencefortheentirefollow-upperiod.
Cumulative incidence analysis was conducted among the at-
risk population comprising only men who did not have a
documented speciﬁc comorbid event during the 12-month
period prior to the index date. Men who left the GPRD
data system during follow-up due to sustained inactivity (no
record of any diagnosis or medication during 12 months),
known transfer out of the system, or death were included in
the at-risk denominator. We evaluated the incidence rates, in
person-years (PY), at 12 and 48 months of follow-up, and
explored the trend between the two periods. The incidence
rate calculation accounts for varying degrees of follow-up,
with PY calculated as the time interval between the index
date and either the date of the event, the date when they
became inactive, the date they were transferred out of the
GPRD system, the date of death, or July 31, 2008, whichever
came ﬁrst.
For capturing the most frequently occurring comor-
bidities and concomitant medication use, we examined the
prevalence over the 12 months prior to the index date (pre-
period) as well as 12 months after the index date (post-
period). We compared the prevalence among cases versus
controls within each period and then the prevalence during
the pre-period versus the post-period within each group.
Kaplan-Meier survival curves were plotted, and all-cause
mortality rates were estimated for men with CaP, men with
elevatedPSAbutnoCaP,andtheirmatchedcontrolsoverthe
10-year period.
Allanalyseswer ec onductedusingSASv ersion9.1.3,with
a signiﬁcance level of α = 0.05. For each comorbidity and
concomitant medication, the signiﬁcance of the prevalence
or cumulative incidence comparison between cases and con-
trols was tested by a two-sided Fisher’s exact test of the
null hypothesis odds ratio, OR = 1 (i.e., odds in cases =
odds in controls). For incidence rate or mortality rate com-
parisons, a two-sided signiﬁcance test was performed on the
null hypothesis rate ratio, RR = 1 (i.e., rate in cases = rate
in controls). This was based on the assumption that the
counts have Poisson distributions, so that the distribution of
log(RR) is approximately Normal, a valid assumption pro-
vided that case and control counts are fairly large (> 30). The
formula for the variance of a log(RR) given, for example,
by Agresti (p. 71) [16] can then be adapted to obtain
var(log(RR)) = 1/n1 +1 /n2,w h e r en1 = count in cases and
n2 = count in controls. The estimate of log(RR) and its vari-
ance are then used to perform a z test of the null hypothesis.
Neither test takes account of the pairing of cases and controls
and is therefore conservative. No adjustment was made for
multiple comparisons.
4. Results
4.1. Baseline Characteristics. In the GPRD, 3,036 CaP pa-
tients and 11,339 men with elevated PSA but no CaP were
identiﬁed. Of these, matching was successful for 86% of the
CaP patients and 89% of those with elevated PSA but no
CaP. Unmatchedcases(420 CaP patients and1,211 menwith
elevated PSA but no CaP) were older than the matched cases
( m e d i a na g e8 1y e a r sv e r s u s6 8o r7 2y e a r s ,r e s p . )a n dh a d
a greater proportion with PSA of >10mg/mL (35% versus
20%, resp.).
CaP patients were slightly older than men with elevated
PSA but no CaP, with median ages of 72 and 68 years,
respectively (Table 1). In both case groups, nearly half of the
men were nonsmokers and 13–16% were current smokers.
Among men with elevated PSA but no CaP, 19.7% had PSA
levels over 10ng/mL; using age-speciﬁc UK cutoﬀ values, as
perNationalHealthServiceguidance,only75%ofthesemen
would have been classiﬁed as having elevated PSA.
4.2. Prevalence and Incidence of Speciﬁc Comorbidities of
Interest. During the 12 months prior to the index date, 28%
of the CaP patients had BPH and 2% had prostatitis. Among
men with elevated PSA but no CaP, 13% had BPH and 0.8%4 Journal of Cancer Epidemiology
Table 1: Baseline characteristics among prostate cancer patients, men with elevated PSA levels but no CaP, and their matched controls in
the General Practice Research Database (GPRD, 1998–2008).
Study population
Prostate cancer patients (cases) and Men with elevated PSA but no CaP (cases) and
matched controls matched controls
Cases Controls Cases Controls
N 2,616 2,616 10,128 10,128
Mean age1, year (SD) 72 (9) 68 (9)
Region1 (%)
Eastern 15% 14%
Southern 36% 38%
Northern 30% 28%
London 10% 9%
Others2 9% 11%
Smoking3 (%)
Never 49% 46% 47% 41%
Current 13% 15% 12% 16%
Past 38% 39% 41% 43%
PSA3 (%)
≤2.5ng/mL 3.5% 100.0% 0.0% 100.0%
2.51–10ng/mL 29.5% — 80.3% —
>10ng/mL 67.0% — 19.7% —
Elevated4 93.9% — 74.9% —
Not elevated 6.1% 100.0% 25.1% 100.0%
1Matching factors.
2Northern Ireland, Scotland, Wales.
3Data on smoking status were missing for 168 CaP patients, 205 CaP controls, 511 men with elevated PSA, and 562 controls for elevated PSA; PSA data were
missing for 1285 CaP patients.
4Based on UK cutoﬀs, ≥3.0 among those with age 50–59 years; ≥4.0 among those with age 60–69 years; >5.0 among those with age 70 and over.
had prostatitis (data not shown). No controls had these di-
agnoses per study design. In both case groups, men had a
3- to 5-fold higher prevalence of UTIs and somewhat higher
prevalence of impotence compared with controls (Table 2).
Men with elevated PSA but no CaP had a lower prevalence of
diabetes than their controls.
The cumulative incidence of UTI was also signiﬁcantly
higher, and the cumulative incidence of stroke was lower
in each case group compared to their matched controls
(Table 3). Compared with controls, CaP patients also had
higher cumulative incidence of impotence and breast disor-
der and lower cumulative incidence of hyperlipidemia. Men
with elevated PSA but no CaP had lower cumulative in-
cidence of congestive heart failure. No diﬀerences between
cases and controls were observed for hypertension, acute
coronary syndrome, angina pectoris, myocardial infarction,
Type II diabetes, and lower extremity arterial disease.
Incidence rates per 10,000 person-years, which account
forvaryingfollow-uptime,demonstratedstatisticallysigniﬁ-
cant diﬀerences between CaP cases and controls for the out-
comes of UTI, impotence, and breast disorder. Speciﬁcally,
CaP patients had a nearly 5-fold higher incidence rate (IR) of
UTI, a 3.5-fold higher IR of impotence, and a 7-fold higher
IR of breast disorders, at 12 months compared with controls
(Table 4). The IRs of UTI and impotence over time were
stable among controls but declined among CaP patients. For
instance, the IRs of UTI, among CaP patients, were 867 per
10,000 person-years [PY], which was almost 5-fold high-
er than controls, during the ﬁrst 12-month period, and
552 per 10,000PY, which was 3.5-fold higher than controls,
duringthe48-monthperiodafterdiagnosis.TheIRsofbreast
disorders changed little over time among both CaP patients
and controls. CaP patients had 40% lower IR of stroke at
12 months and 30% to 40% higher IR of hypertension and
congestive heart failure at 48 months only. There were no
other outcomes that diﬀered substantially between CaP pa-
tients and controls.
Men with elevated PSA but no CaP also had a higher IR
of UTI (over 5-fold for the ﬁrst 12-month period and 2.8-
fold for the 48-month period) and slightly higher IR of hy-
pertension, compared with controls (Table 4). IRs of im-
potence and breast disorders were similar between cases and
controls. Men with elevated PSA experienced a 40% high-
er rate of type II diabetes and a 60% lower rate of lower-
extremity arterial occlusive disease during the ﬁrst 12-month
period after the ﬁrst elevated PSA test result. However,
the diﬀerences were smaller and not statistically signiﬁcant
for the 48-month period. No other outcomes diﬀered sub-
stantially between elevated PSA/no CaP cases and their con-
trols.Journal of Cancer Epidemiology 5
Table 2:Prevalence(and95%CI)ofselectedcomorbiditiesofinterestamongCaPpatientsandmenwithelevatedPSAbutnoCaP,compared
with matched controls, during 12 months prior to the index date in the General Practice Research Database (GPRD, 1998–2008)1.
Comorbidity
CaP patients and matched controls Men with elevated PSA but no CaP and matched controls
Cases
(n = 2,616)
Controls
(n = 2,616) OR (95% CI)2 Cases
(n = 10,128)
Controls
(n = 10,128) OR (95% CI)2
Urinary tract
infection 8.3 (7.2, 9.3) 2.6 (2.0, 3.2) 3.4 (2.5, 4.5)∗ 7.6 (7.1, 8.1) 1.7 (1.5, 2.0) 4.7 (4.0, 5.6)∗
Impotence 4.0 (3.2, 4.7) 2.4 (1.9, 3.0) 1.6 (1.2, 2.3)∗ 3.7 (3.3, 4.1) 2.9 (2.5, 3.2) 1.3 (1.1, 1.5)∗
Breast disorders 0.2 (0.0, 0.4) 0.2 (0.0, 0.4) 0.8 (0.2, 3.3) 0.1 (0.1, 0.2) 0.2 (0.1, 0.3) 0.6 (0.3, 1.3)
Hypertension 7.5 (6.5, 8.5) 6.7 (5.7, 7.6) 1.1 (0.9, 1.4) 5.6 (5.1, 6.0) 5.2 (4.8, 5.6) 1.1 (0.95, 1.2)
Stroke 1.7 (1.2, 2.2) 1.6 (1.2, 2.1) 1.0 (0.6, 1.6) 1.0 (0.8, 1.2) 0.9 (0.8, 1.1) 1.1 (0.8, 1.4)
Acute coronary
syndrome 0.9 (0.6, 1.3) 1.0 (0.6, 1.4) 0.9 (0.5, 1.7) 0.6 (0.5, 0.8) 0.8 (0.7, 1.0) 0.7 (0.5, 1.02)
Angina pectoris 2.7 (2.1, 3.3) 3.0 (2.4, 3.7) 0.9 (0.6, 1.3) 1.6 (1.4, 1.9) 1.8 (1.5, 2.0) 0.9 (0.7, 1.1)
Arrythmia 3.0 (2.3, 3.6) 2.7 (2.1, 3.3) 1.1 (0.8, 1.5) 1.6 (1.4, 1.9) 1.7 (1.5, 2.0) 0.9 (0.7, 1.2)
Myocardial infarction 0.6 (0.3, 0.9) 0.7 (0.4, 1.0) 0.9 (0.4, 1.8) 0.4 (0.2, 0.5) 0.6 (0.4, 0.7) 0.7 (0.4, 1.02)
Congestive heart
failure 1.4 (0.9, 1.8) 1.5 (1.0, 2.0) 0.9 (0.6, 1.5) 0.7 (0.6, 0.9) 0.9 (0.7, 1.1) 0.8 (0.6, 1.1)
Hyperlipidemia 2.4 (1.8, 3.0) 2.4 (1.8, 3.0) 1.0 (0.7, 1.5) 2.0 (1.8, 2.3) 2.4 (2.1, 2.7) 0.8 (0.7, 1.02)
Low-extremity
arterial occlusive
disease
0.6 (0.3, 0.9) 0.5 (0.2, 0.8) 1.1 (0.5, 2.6) 0.4 (0.3, 0.5) 0.5 (0.3, 0.6) 0.8 (0.5, 1.3)
Type II diabetes 2.3 (1.7, 2.8) 2.5 (1.9, 3.1) 0.9 (0.6, 1.3) 2.0 (1.7, 2.3) 3.1 (2.7, 3.4) 0.6 (0.5, 0.8)∗
1Index date was the date of initial CaP diagnosis for prostate cancer (CaP) patients; the date of ﬁrst elevated PSA test result for men with elevated PSA; the
same index date as their matched cases for controls. CI = conﬁdence interval.
2Odds ratio and 95% conﬁdence interval.
∗Signiﬁcant diﬀerence between cases and their matched controls (P<0.05).
Table 3: Cumulative incidence (%and 95% CI) of speciﬁc comorbidities of interest across total follow-up after index date among CaP
patients, men with elevated PSA but no CaP, and their matched controls in the General Practice Research Database (GPRD, 1998–2008)1.
Comorbidity
CaP patients and matched controls Men with elevated PSA but no CaP and matched controls
Cases
(n = 2,616)
Controls
(n = 2,616) OR (95% CI)2 Cases
(n = 10,128)
Controls
(n = 10,128) OR (95% CI)2
Urinary tract
infection 18.0 (16.2, 19.9) 7.7 (6.6, 8.9) 2.6 (2.2, 3.2)∗ 11.0 (10.3, 11.7) 4.5 (4.1, 5.0) 2.6 (2.3, 2.9)∗
Impotence 12.7 (11.3, 14.3) 7.0 (6.0, 8.1) 1.9 (1.6, 2.4)∗ 6.6 (6.0, 7.1) 6.3 (5.8, 6.9) 1.0 (0.9, 1.2)
Breast disorders 3.3 (2.7, 4.1) 1.1 (0.7, 1.6) 3.0 (2.0, 4.8)∗ 0.7 (0.5, 0.8) 0.6 (0.4, 0.7) 1.2 (0.8, 1.7)
Hypertension 15.2 (13.3, 17.1) 14.6 (12.8, 16.5) 1.0 (0.9, 1.3) 12.6 (11.8, 13.5) 11.8 (11, 12.7) 1.1 (0.97, 1.2)
Stroke 4.7 (3.9, 5.7) 7.1 (6.0, 8.2) 0.7 (0.5, 0.8)∗ 2.9 (2.5, 3.2) 3.4 (3.0, 3.8) 0.8 (0.7, 0.99)∗
Acute coronary
syndrome 3.6 (2.8, 4.4) 3.8 (3.0, 4.7) 0.9 (0.7, 1.3) 2.1 (1.8, 2.4) 2.3 (2.0, 2.7) 0.9 (0.7, 1.07)
Angina pectoris 3.7 (2.9, 4.6) 3.4 (2.6, 4.2) 1.1 (0.8, 1.5) 1.9 (1.6, 2.2) 2.2 (1.9, 2.5) 0.8 (0.7, 1.04)
Arrhythmia 6.5 (5.5, 7.7) 7.8 (6.7, 9.0) 0.8 (0.7, 1.04) 4.5 (4.1, 5.0) 4.8 (4.4, 5.3) 0.9 (0.8, 1.1)
Myocardial infarction 2.9 (2.3, 3.7) 3.1 (2.4, 3.9) 0.9 (0.7, 1.3) 1.7 (1.4, 1.9) 1.9 (1.6, 2.2) 0.9 (0.7, 1.1)
Congestive heart
failure 5.6 (4.7, 6.6) 5.2 (4.4, 6.2) 1.1 (0.8, 1.4) 1.8 (1.6, 2.1) 2.3 (2.0, 2.6) 0.8 (0.6, 0.9)∗
Hyperlipidemia 6.6 (5.6, 7.8) 8.6 (7.4, 9.9) 0.8 (0.6, 0.9)∗ 5.9 (5.4, 6.4) 5.6 (5.2, 6.2) 1.0 (0.9, 1.2)
Lower extremity
arterial occlusive
disease
1.5 (1.0, 2.0) 2.2 (1.6, 2.8) 0.7 (0.4, 1.05) 0.8 (0.6, 1.0) 1.0 (0.8, 1.3) 0.7 (0.5, 1.002)
Diabetes type II 5.6 (4.7, 6.7) 6.4 (5.4, 7.5) 0.9 (0.7, 1.1) 3.9 (3.5, 4.4) 4.4 (3.9, 4.8) 0.9 (0.8, 1.04)
1Index date was the date of initial CaP diagnosis for prostate cancer (CaP) patients; the date of ﬁrst elevated PSA test result for men with elevated PSA; the
same index date as their matched cases for controls. CI = conﬁdence interval; cumulative incidence is across total follow-up period.
2Odds ratio and 95% conﬁdence interval.
∗Signiﬁcant diﬀerence between cases and their matched controls (P<0.05).6 Journal of Cancer Epidemiology
4.3. Prevalence of General Comorbidities. Across all four
groups, cardiovascular-related issues were the most common
comorbidity among men of this age (data not shown). CaP
patients had higher prevalence of urinary tract signs and
symptoms than matched controls; the prevalence was 43%
during the 12-month period prior to CaP diagnosis then
dropped to 19% during the 12-month period after CaP
diagnosis and was 7% and 8% among controls in the 12-
month period before and after the index date, respectively
(Figure 1).MenwithelevatedPSAalsohadhigherprevalence
of urinary tract signs and symptoms (29% and 31% during
the 12-month period before and after the elevated PSA re-
sults, resp.), compared with controls (6% to7% across both
periods).
4.4. Prevalence of Concomitant Medication Use. Medication
use was examined in the subgroup of men in GPRD from
2003 to 2008. During both the 12-month period before and
the 12-month period after the index date, the most com-
monly used medications among men across the four cohorts
included nonopioid analgesics and nonsteroidal anti-inﬂam-
matorydrugs(NSAIDs,40%to50%),statinsandantiplatelet
drugs (27% to 37%), opioid analgesics, angiotensin-convert-
ing enzyme inhibitors, beta-adrenoceptor blocking drugs,
andcalciumchannelblockers(20%to30%,datanotshown).
Table 5 highlighted the prevalence of concomitant medi-
cationusethatwasstatisticallysigniﬁcantlydiﬀerentbetween
CaPpatientsandtheircontrolsorbetweenmenwithelevated
PSA but no CaP and their controls. Uses of alpha blockers in
urinaryretention,alphaadrenoceptorblockingdrugs,sulph-
onamides and trimethoprim, and quinolones were 2- to 4-
fold more common for CaP patients before and after index
date, compared to matched controls. For men with elevated
PSA compared to controls, use of these same medications
was 2- to 4-fold more common for cases than controls before
index date and 3- to 5-fold more common after index date.
After diagnosis, use of lidocaine/lignocaine in anaesthesia
was 10-fold higher in CaP patients than controls, compared
to only 2-fold higher prediagnosis. Prostate cancer drugs
and gonadorelin analogues, drugs aﬀecting gonadotrophins,
male sex hormones, and antagonists were commonly used
among CaP patients, especially after cancer diagnosis. More
menwithelevatedPSAbutnoCaPwereonalpha-blockersin
urinary retention, alpha-adrenoceptor blocking drugs, male
sex hormones and antagonists, and statins during the 12-
month period after (versus before) the index date.
4.5. All-Cause and Cause-Speciﬁc Mortality and Survival.
CaP patients had the poorest survival, with a 2.6-fold higher
all-cause mortality compared to their matched controls
(Figure 2). Controls matched to CaP patients had slightly
higher all-cause mortality than controls matched to men
with elevated PSA, likely due to their older age. In contrast,
all-cause mortality was slightly lower among men with
elevated PSA compared to their matched controls. Of the
2,075 deaths in these four cohorts, we were able to link elec-
tronic medical data to death certiﬁcates for 1,226 (59%)
patients. Of these, the underlying causes of death were avail-
able for 1,194 men. Table 6 presents the underlying causes of
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Figure 1: Prevalence of urinary tract signs and symptoms among
CaP patients, men with elevated PSA but no CaP, and matched
controls during 12 months prior to and 12 months after the index
date in the General Practice Research Database (GPRD, 1998–2008)
(Index date was the date of initial CaP diagnosis for prostate cancer
(CaP) patients; the date of ﬁrst elevated PSA test result for men
with elevated PSA but no CaP; the same index date as their matched
casesforcontrols).Theprevalenceoddsratios,OR(95%conﬁdence
interval, CI), were 11.3 (9.5–13.6) during 12 months prior to the
index date and 2.9 (2.5–3.5) during 12-months post the index date
for CaP patients, compared to controls, and were 6.2 (5.6–6.8) dur-
ing 12 months prior to the index date and 6.1 (5.6–6.7) during
12 months after the index date for men with elevated PSA but no
CaP, compared to controls. AmongCaP patients, the prevalence OR
(95% CI) was 3.2 (2.8–3.6) 12 months prior to versus 12 months
after the index date.
death among men who died within each group. Frequencies
of more than 2% for individual event types and of more
than 3% for systems of diseases were reported. Among CaP
patients, nearly 60% (n = 220) of the deaths were ascribed to
neoplasms, and 58% (n = 213) to CaP. In contrast, 12 men
with elevated PSA died of CaP (i.e., 4.6% of 197 deaths), and
no men died of CaP among controls. Next to neoplasms as
an underlying cause, 25% of the deaths among CaP patients
were ascribed to diseases of the circulatory system compared
to men with elevated PSA and no CaP (46%) and men in the
twocontrolgroups(52%and49%).Thepercentageofdeaths
due to other underlying causes, such as respiratory and
nervous systems, was lower among CaP patients compared
to the other three groups of men. Among men with elevated
PSA with no CaP and men in the two control groups, 46%
to 51% of the deaths were due to diseases of circulatory sys-
tem, as mentioned above, 17% to 21% due to diseases of
respiratory systems, and 8% to 13% due to neoplasms.
5. Discussion
This study examined the prevalence and incidence of comor-
bidities and the prevalence of concomitant medication use
among men with CaP, men deemed at increased risk of CaP
duetoelevatedPSA,andcontrolgroupsthatwerematchedto
thesemenonage,practice,anddurationandcalendarperiod
of follow-up in the GPRD.Journal of Cancer Epidemiology 7
Table 4: Incidence rates (IR, per 10,000 person-years; 95% CI) for selected comorbidities among CaP patients and men with elevated PSA
but no CaP, compared with matched controls, during 12 and 48 months after the index date in the General Practice Research Database
(GPRD, 1998–2008)1.
Comorbidity
CaP patients and matched controls Men with elevated PSA but no CaP and matched controls
Cases
(n = 2,616)
Controls
(n = 2,616) RR (95% CI)2 Cases
(n = 10,128)
Controls
(n = 10,128) RR (95% CI)2
Urinary tract infection
<12 mo 867 (740, 1009) 179 (128, 243) 4.9 (3.4, 6.8)∗ 569 (517, 625) 104 (84, 128) 5.4 (4.3, 6.8)∗
<48 mo 552 (492, 616) 156 (129, 188) 3.5 (2.8, 4.4)∗ 367 (344, 395) 130 (116, 145) 2.8 (2.5, 3.2)∗
Impotence
<12 mo 642 (539, 759) 181 (130, 246) 3.5 (2.5, 5.0)∗ 256 (223, 292) 237 (205, 272) 1.1 (0.9, 1.3)
<48 mo 442 (392, 498) 174 (145, 207) 2.5 (2.1, 3.1)∗ 215 (197, 235) 197 (180, 215) 1.1 (0.96, 1.2)
Breast disorders
<12 mo 90 (56, 136) 12 (3, 35) 7.4 (2.2, 24.8)∗ 18 (10, 28) 14 (7, 23) 1.3 (0.6, 2.7)
<48 mo 93 (72, 118) 23 (14, 36) 4.0 (2.4, 6.6)∗ 18 (13, 23) 16 (11, 21) 1.1 (0.7, 1.7)
Hypertension
<12 mo 508 (403, 634) 401 (309, 511) 1.3 (0.9, 1.8) 499 (444, 558) 355 (310, 405) 1.4 (1.2, 1.7)∗
<48 mo 455 (395, 522) 354 (305, 410) 1.3 (1.05, 1.6)∗ 409 (380, 441) 359 (332, 388) 1.1 (1.02, 1.3)∗
Stroke
<12 mo 110 (71, 162) 185 (13, 251) 0.6 (0.4, 0.97)∗ 78 (61, 98) 93 (75, 116) 0.8 (0.6, 1.1)
<48 mo 127 (102, 156) 157 (129, 188) 0.8 (0.6, 1.1) 83 (72, 95) 97 (86, 110) 0.9 (0.7, 1.0)
Acute coronary syndrome
<12 mo 129 (86, 185) 76 (44, 121) 1.7 (0.9, 3.1) 52 (39, 70) 56 (41, 73) 0.9 (0.6, 1.4)
<48 mo 96 (75, 123) 78 (60, 101) 1.2 (0.9, 1.7) 62 (53, 72) 60 (51, 71) 1.0 (0.8, 1.3)
Angina pectoris
<12 mo 113 (72, 168) 81 (47, 129) 1.4 (0.7, 2.6) 68 (51, 87) 76 (58, 97) 0.9 (0.6, 1.3)
<48 mo 104 (81, 133) 80 (60, 104) 1.3 (0.9, 1.9) 60 (51, 71) 66 (56, 77) 0.9 (0.7, 1.1)
Arrhythmia
<12 mo 156 (108, 218) 134 (91, 192) 1.2 (0.7, 1.9) 134 (111, 161) 131 (108, 157) 1.0 (0.8, 1.3)
<48 mo 164 (134, 198) 139 (113, 169) 1.2 (0.9, 1.5) 134 (120, 149) 140 (125, 155) 1.0 (0.8, 1.1)
Myocardial infarction
<12 mo 96 (60, 145) 61 (34, 103) 1.6 (0.8, 3.1) 35 (24, 50) 50 (37, 67) 0.7 (0.4, 1.1)
<48 mo 77 (58, 101) 61 (45, 82) 1.3 (0.8, 1.9) 50 (42, 59) 50 (42, 59) 1.0 (0.8, 1.3)
Congestive heart failure
<12 mo 144 (100, 201) 85 (52, 131) 1.7 (0.98, 3.0) 49 (36, 65) 58 (43, 75) 0.8 (0.6, 1.3)
<48 mo 145 (118, 176) 106 (84, 132) 1.4 (1.02, 1.8)∗ 52 (44, 62) 65 (56, 75) 0.8 (0.6, 1.003)
Hyperlipidemia
<12 mo 140 (95, 199) 196 (142, 264) 0.7 (0.4, 1.1) 234 (202, 269) 194 (165, 226) 1.2 (0.98, 1.5)
<48 mo 156 (128, 189) 187 (156, 221) 0.8 (0.6, 1.1) 189 (172, 207) 172 (156, 190) 1.1 (0.96, 1.3)
Lower-extremity arterial occlusive disease
<12 mo 50 (26, 87) 33 (14, 65) 1.5 (0.6, 3.6) 19 (11, 30) 44 (31, 59) 0.4 (0.2, 0.8)∗
<48 mo 34 (22, 50) 46 (32, 63) 0.7 (0.4, 1.2) 23 (18, 29) 29 (23, 37) 0.8 (0.6, 1.1)
Diabetes, Type II
<12 mo 131 (89, 188) 97 (61, 147) 1.4 (0.8, 2.3) 181 (154, 211) 126 (103, 152) 1.4 (1.1, 1.8)∗
<48 mo 154 (126, 187) 144 (118, 174) 1.1 (0.8, 1.4) 122 (109, 136) 126 (112, 141) 1.0 (0.8, 1.1)
1Index date was the date of initial CaP diagnosis for prostate cancer (CaP) patients; the date of ﬁrst elevated PSA test result for men with elevated PSA; the
same index date as their matched cases for controls. CI = conﬁdence interval.
2Rate ratio (95% conﬁdence interval) comparing cases and their controls.
∗Signiﬁcant diﬀerence between cases and their matched controls (P<0.05).8 Journal of Cancer Epidemiology
Table 5: Prevalence (and 95% CI) of concomitant medication use that was statistically signiﬁcantly diﬀerent between CaP patients and their
controls or between men with elevated PSA but no CaP and their controls in the General Practice Research Database (GPRD, 2003–2008)1.
Cases Controls OR (95% CI)
CaP patients (n = 1, 345) and matched controls (n = 1, 345): during 12 months prior to the index date
Alpha blockers (in urinary retention) 24.3 (22.0, 26.6) 7.1 (5.7, 8.4) 4.2 (3.3, 5.4)
Alpha adrenoceptor blocking drugs 20.7 (18.6, 22.9) 6.7 (5.4, 8.0) 3.6 (2.8, 4.7)
Sulphonamides and trimethoprim 12.2 (10.4, 13.9) 3.9 (2.9, 5.0) 3.4 (2.4, 4.8)
Quinolones 8.8 (7.3, 10.3) 3.1 (2.2, 4.1) 3.0 (2.1, 4.4)
Lidocaine/lignocaine (in anaesthesia) 6.4 (5.1, 7.7) 3.0 (2.1, 3.9) 2.2 (1.5, 3.4)
Cephalosporins and other beta lactams 6.9 (5.6, 8.3) 4.2 (3.1, 5.2) 1.7 (1.2, 2.4)
Osmotic laxatives 10.6 (8.9, 12.2) 7.4 (6.0, 8.8) 1.5 (1.1, 2.0)
Thiazides and related diuretics 20.3 (18.1, 22.4) 17.0 (14.9, 19.0) 1.2 (1.02, 1.5)
Antiplatelet drugs 29.7 (27.2, 32.1) 34.3 (31.8, 36.9) 0.8 (0.7, 0.95)
Statins 28.8 (26.4, 31.3) 32.8 (30.3, 35.3) 0.8 (0.7, 0.98)
Prostate cancer and gonadorelin analogues 7.9 (6.4, 9.3) —2
Emollient skin preparations 7.9 (6.4, 9.3) —2
Male sex hormones and antagonists 6.2 (5.0, 7.5) —2
CaP patients (n = 1,345) and matched controls (n = 1,345): during 12 months after the index date
Lidocaine/lignocaine (in anaesthesia) 17.8 (15.8, 19.9) 2.0 (1.3, 2.8) 10.6 (7.0, 16.5)
Alpha blockers (in urinary retention) 26.8 (24.5, 29.2) 8.0 (6.5, 9.4) 4.2 (3.4, 5.4)
Alpha adrenoceptor blocking drugs 22.8 (20.6, 25.1) 7.4 (6.0, 8.8) 3.7 (2.9, 4.8)
Quinolones 8.4 (6.9, 9.9) 3.3 (2.4, 4.3) 2.6 (1.8, 3.9)
Drugs for urinary frequency, enuresis and incontinence 10.6 (8.9, 12.2) 4.7 (3.6, 5.8) 2.4 (1.8, 3.3)
Prophylaxis of migraine 6.5 (5.2, 7.8) 3.0 (2.1, 4.0) 2.2 (1.5, 3.3)
Motility stimulants 3.9 (2.8, 4.9) 1.8 (1.1, 2.5) 2.2 (1.3, 3.8)
Drugs for erectile dysfunction 12.3 (10.6, 14.1) 5.9 (4.6, 7.1) 2.3 (1.7, 3.0)
Osmotic laxatives 15.0 (13.1, 16.9) 7.6 (6.2, 9.0) 2.2 (1.7, 2.8)
Sulphonamides and trimethoprim 10.7 (9.1, 12.4) 4.6 (3.5, 5.7) 1.9 (1.4, 2.6)
Vasodilator antihypertensive drugs 7.4 (6.0, 8.8) 3.9 (2.8, 4.9) 2.0 (1.4, 2.9)
Compound haemorrhoidal preparations with
corticosteroids 4.2 (3.2, 5.3) 2.2 (1.4, 3.0) 1.9 (1.2, 3.1)
Stimulant laxatives 8.8 (7.3, 10.3) 4.8 (3.7, 6.0) 1.9 (1.4, 2.6)
Anxiolytics and neuroleptics (in anaesthesia) 6.0 (4.8, 7.3) 3.3 (2.4, 4.3) 1.9 (1.3, 2.8)
Tricyclic and related antidepressant drugs 7.1 (5.7, 8.4) 4.0 (3.0, 5.1) 1.8 (1.3, 2.6)
Oral iron 6.6 (5.3, 7.9) 4.0 (3.0, 5.1) 1.7 (1.2, 2.4)
Neuropathic pain 6.5 (5.2, 7.9) 4.0 (3.0, 5.1) 1.7 (1.2, 2.4)
Drugs used in nausea and vertigo 9.4 (7.8, 10.9) 5.9 (4.6, 7.1) 1.7 (1.2, 2.2)
Antimotility drugs 6.5 (5.2, 7.9) 4.2 (3.1, 5.2) 1.6 (1.1, 2.3)
Hypnotics 9.4 (7.8, 10.9) 6.8 (5.4, 8.1) 1.4 (1.1, 1.9)
Acute attacks of gout 13.9 (12.1, 15.8) 10.3 (8.7, 12.0) 1.4 (1.1, 1.8)
Urinary-tract infections 20.1 (18.0, 22.3) 15.2 (13.3, 17.2) 1.4 (1.1, 1.7)
Broad-spectrum penicillins 22.2 (20.0, 24.5) 18.2 (16.2, 20.3) 1.3 (1.1, 1.6)
Topical corticosteroids 21.5 (19.3, 23.7) 17.6 (15.6, 19.7) 1.3 (1.1, 1.6)
Statins 32.2 (29.7, 34.7) 37.2 (34.7, 39.8) 0.8 (0.7, 0.9)
Antiplatelet drugs 32.1 (29.6, 34.6) 37.4 (34.8, 40.0) 0.8 (0.7, 0.9)
Prostate cancer and gonadorelin analogues 71.8 (69.4, 74.2) —2
Drugs aﬀecting gonadotrophins 34.1 (31.5, 36.6) —2
Breast cancer 23.9 (21.6, 26.1) —2
Male sex hormones and antagonists 16.8 (14.8, 18.8) —2Journal of Cancer Epidemiology 9
Table 5: Continued.
Cases Controls OR (95% CI)
Ventricular arrhythmias 11.8 (10.1, 13.5) —2
Leg bags 6.9 (5.6, 8.3) —2
Night drainage bags 5.1 (3.9, 6.2) —2
M e nw i t he l e v a t e dP S Ab u tn oC a P( n = 7,725) and matched controls (n = 7,725): during 12 months prior to the index date
Sulphonamides and trimethoprim 10.6 (9.9, 11.3) 3.0 (2.6, 3.4) 3.9 (3.3, 4.5)
Alpha blockers (in urinary retention) 16.8 (15.9, 17.6) 7.4 (6.8, 7.9) 2.5 (2.3, 2.8)
Alpha adrenoceptor blocking drugs 14.3 (13.5, 15.1) 6.8 (6.2, 7.4) 2.3 (2.0, 2.6)
Quinolones 5.6 (5.1, 6.1) 2.8 (2.4, 3.2) 2.1 (1.8, 2.5)
Male sex hormones and antagonists 3.2 (2.8, 3.6) 1.6 (1.3, 1.8) 2.1 (1.6, 2.6)
Cephalosporins and other beta lactams 7.2 (6.6, 7.7) 3.6 (3.2, 4.1) 2.0 (1.8, 2.4)
Biguanides 4.4 (3.9, 4.8) 6.6 (6.0, 7.1) 0.7 (0.6, 0.8)
Sulphonylureas 3.2 (2.8, 3.6) 4.7 (4.2, 5.2) 0.7 (0.6, 0.8)
Diagnostic and monitoring agents for diabetes mellitus 1.7 (1.4, 2.0) 2.3 (2.0, 2.6) 0.7 (0.6, 0.9)
Other antianginal drugs 1.3 (1.1, 1.6) 1.8 (1.5, 2.1) 0.7 (0.6, 0.9)
Nitrates 7.7 (7.1, 8.3) 9.4 (8.7, 10) 0.8 (0.7, 0.9)
Loop diuretics 5.9 (5.4, 6.5) 7.4 (6.8, 8.0) 0.8 (0.7, 0.9)
Nonopioid analgesics 39.1 (38.0, 40.2) 43.8 (42.7, 44.9) 0.8 (0.8, 0.9)
Control of epilepsy 4.2 (3.8, 4.7) 5.1 (4.6, 5.6) 0.8 (0.7, 0.96)
Neuropathic pain 3.9 (3.5, 4.3) 4.6 (4.2, 5.1) 0.8 (0.7, 0.98)
Antimotility drugs 2.8 (2.4, 3.1) 3.3 (2.9, 3.7) 0.8 (0.7, 0.995)
Statins 28.4 (26.6, 30.3) 32.5 (30.7, 34.4) 0.8 (0.8, 0.9)
Antiplatelet drugs 26.5 (24.6, 28.4) 30.5 (28.7, 32.4) 0.8 (0.8, 0.9)
Opioid analgesics 19.6 (18.7, 20.5) 21.8 (20.8, 22.7) 0.9 (0.8, 0.9)
Beta adrenoceptor blocking drugs 18.3 (17.5, 19.2) 19.9 (19.0, 20.7) 0.9 (0.8, 0.98)
M e nw i t he l e v a t e dP S Ab u tn oC a P( n = 7,725) and matched controls (n = 7,725): during 12 months after the index date
Male sex hormones and antagonists 10.6 (10.0, 11.3) 1.7 (2.0, 1.4) 6.9 (5.7, 8.4)
Alpha blockers (in urinary retention) 32.2 (31.1, 33.2) 8.0 (8.6, 7.4) 5.5 (5.0, 6.0)
Alpha adrenoceptor blocking drugs 27.4 (26.4, 28.4) 7.3 (7.9, 6.7) 4.8 (4.3, 5.3)
Sulphonamides and trimethoprim 10.2 (9.5, 10.9) 2.8 (3.2, 2.4) 4.0 (3.4, 4.7)
Quinolones 9.3 (8.7, 10.0) 3.1 (3.4, 2.7) 3.3 (2.8, 3.8)
Cephalosporins and other beta lactams 7.4 (6.8, 8.0) 3.9 (4.3, 3.4) 2.0 (1.7, 2.3)
Lidocaine/lignocaine (in anaesthesia) 3.5 (3.1, 3.9) 2.4 (2.7, 2.0) 1.5 (1.2,1.8)
Compound haemorrhoidal preparations with
corticosteroids 2.9 (2.5, 3.3) 2.3 (2.6, 1.9) 1.3 (1.1,1.6)
Drugs for urinary frequency, enuresis and incontinence 6.3 (5.7, 6.8) 5.2 (5.6, 4.7) 1.2 (1.1, 1.4)
Drugs for erectile dysfunction 7.4 (6.8, 8.0) 6.3 (6.9, 5.8) 1.2 (1.08, 1.4)
Vasodilator antihypertensive drugs 4.9 (4.4, 5.4) 4.2 (4.7, 3.8) 1.2 (1.003, 1.4)
Biguanides 4.9 (4.4, 5.4) 7.2 (7.8, 6.7) 0.7 (0.6, 0.8)
Sulphonylureas 3.4 (3.0, 3.8) 4.7 (5.2, 4.2) 0.7 (0.6, 0.8)
Emollient bath additives 1.7 (1.4, 2.0) 2.3 (2.6, 2.0) 0.7 (0.6, 0.9)
Calcium supplements 2.2 (1.8, 2.5) 2.7 (3.1, 2.3) 0.8 (0.6, 0.98)
Vitamin D 1.9 (1.6, 2.2) 2.4 (2.8, 2.1) 0.8 (0.6, 0.98)
Nitrates 7.5 (6.9, 8.1) 9.4 (10, 8.7) 0.8 (0.7, 0.9)
Neuropathic pain 4.3 (3.9, 4.8) 5.1 (5.6, 4.6) 0.8 (0.7, 0.98)
Antiplatelet drugs 29.4 (28.4, 30.4) 32.9 (34.0, 31.9) 0.8 (0.8, 0.9)
Nonopioid analgesics 42.6 (41.5, 43.7) 45.9 (47.0, 44.7) 0.9 (0.8, 0.9)10 Journal of Cancer Epidemiology
Table 5: Continued.
Cases Controls OR (95% CI)
Beta adrenoceptor blocking drugs 18.5 (17.6, 19.4) 20.6 (21.5, 19.7) 0.9 (0.8, 0.9)
Loop diuretics 7.0 (6.4, 7.6) 8.1 (8.7, 7.5) 0.9 (0.8, 0.96)
Emollient skin preparations 7.4 (6.8, 8.0) 8.5 (9.1, 7.9) 0.9 (0.8, 0.97)
Nonsteroidal anti-inﬂammatory drugs 42.8 (41.7, 43.9) 44.7 (45.8, 43.6) 0.9 (0.9, 0.98)
1Medications, listed by class per British National Formulary (BNF) header within the product ﬁles, were assessed among a subgroup of men in GPRD within
the latter ﬁve years (i.e., index dates between August 1, 2003 and July 31, 2008), in order to provide a more up-to-date pattern for medication use. OR = odds
ratio, CI = conﬁdence interval. This table, ranked by magnitude of the OR, includes only medications with signiﬁcant ORs. For medications used by less than
2% in cases (or controls), only those used by >5% by their matched patients were included. Index date was the date of initial CaP diagnosis for prostate cancer
(CaP) patients; the date of ﬁrst elevated PSA test result for men with elevated PSA but no CaP; the same index date as their matched cases for controls.
2Blanks indicate that the frequency of medication use was <2%.
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Groups N Death Mortality rate (95% CI),
per 10,000 person-year
CaP patients (group A) 2,616 682 661 (613, 713)
Controls for CaP (group B) 2,616 311 256 (228, 286)
Men with elevated PSA but no CaP (group C) 10,128 476 136 (124, 148)
Controls for men with elevated PSA but no CaP (group D) 10,128 606 171 (158, 185)
Figure 2: Kaplan-Meier survival curve for CaP patients, men with elevated PSA but no CaP and matched controls in the General Practice
ResearchDatabase(GPRD,1998–2008).Therateratio,RR(95%conﬁdenceinterval,CI),was2.6(2.3–3.0)forCaPpatientsand0.8(0.7–0.9)
for men with elevated PSA but no CaP, compared to matched controls.
We included men with elevated PSA identiﬁed between
August 1, 1998 and July 31, 2008 and found that a fairly
high proportion (∼20%) of these men had PSA levels over
10ng/mL but had never been diagnosed with CaP. Although
this observation seems inconsistent with the high speciﬁcity
of the PSA test at the level of >10ng/mL [13], it may reﬂect
the reality in UK. According to the UK Prostate Cancer
Risk Management Programme [14], CaP screening was not
oﬀered for asymptomatic men during this time period, given
that the extent of beneﬁt and harm of such screening are still
under debate [18–20]. Men with elevated PSA may or may
notbefurtherevaluatedforCaP,duetothelackofagreement
among primary care physicians regarding what PSA cutoﬀs
should trigger patient referrals [21, 22].
Compared with controls, CaP patients had signiﬁcantly
higher incidence of UTI (2- to 5-fold), impotence (2- to
3-fold), and breast disorders (3- to 7-fold) after diagnosis,
which is consistent with earlier studies [23, 24]. Men with
elevated PSA also had higher incidence (3- to 5-fold) of UTI,
compared with controls. For several conditions, including
UTI and impotence among CaP patients and UTI, hyperten-
sion,anddiabetesamongmenwithelevatedPSAbutnoCaP,
the incidence was the highest, and the diﬀerences between
cases and controls were the greatest during the ﬁrst 12
months of follow-up; rates were lower and diﬀerences were
smaller at 48 months of follow-up. A plausible explanation
may be that previously undiagnosed conditions are coming
to medical attention after CaP diagnoses or the elevated PSA
ﬁndings due to more intense medical scrutiny.
The prevalence and incidence of hypertension and car-
diovascular-related comorbidities, including acute coronary
syndrome, angina pectoris, arrhythmia, myocardial infarc-
tion, congestive heart failure, and lower extremity arterialJournal of Cancer Epidemiology 11
Table 6: Underlying causes of deaths: CaP patients, men with elevated PSA but no CaP, and matched controls in the General Practice
Research Database (GPRD, 1998–2008)1.
CaP patients and matched controls Men with elevated PSA but no CaP and
matched controls
Cases (369 deaths) Controls (263 deaths) Cases (197 deaths) Controls (365 deaths)
Neoplasms (% among all deaths) 59.6 8.1 13.3 8.8
Prostate cancer 57.7 0.0 4.6 0.0
Diseases of the circulatory system (%) 24.9 51.8 46.4 49.3
Acute myocardial infarction 5.7 11.7 8.7 12.3
Chronic ischaemic heart disease 4.6 11.2 10.6 10.1
Atherosclerotic heart disease 2.7 6.1 3.4 8.2
S t r o k e ,n o ts p e c i ﬁ e da s
haemorrhage or infarction 3.0 5.1 4.2 4.9
Cerebral infarction 0.8 2.5 1.5 0.8
Cerebrovascular disease 1.4 2.0 1.1 1.4
Abdominal aortic aneurysm,
ruptured 0.3 2.0 1.9 1.4
Diseases of the respiratory system (%) 6.8 17.3 19.0 21.4
Bronchopneumonia 2.2 6.1 3.8 4.1
Pneumonia 0.3 3.6 4.2 3.0
Chronic obstructive pulmonary
disease 2.2 2.5 7.2 6.8
Diseases of the nervous system (%) 1.4 6.6 4.2 3.8
Parkinson’s disease 1.1 2.0 1.5 1.4
Alzheimer’s disease 0.3 2.5 1.5 0.5
Diseases of the digestive system (%) 3.5 4.1 3.4 4.4
Diseases of the genitourinary system
(%) 0.5 1.0 3.8 1.4
External causes of morbidity and
mortality2(%) 0.8 2.5 3.0 2.2
Others3(%) 2.4 8.6 6.8 8.8
1The linkage to the death certiﬁcate data was available for 1,226 patients, that is, 59% of 2,075 deaths. Of these, 1,194 men had underlying cause of death
record. The underlying causes of death were recorded and described according to the International Statistical Classiﬁcation of Diseases and RelatedH e a l t h
Problems 10th Revision (ICD-10) [17]. Frequencies of more than 2% for individual events and of more than 3% for systems of diseases were reported.
2Including accidents, intentional self-harm, event of undetermined intent, and complications of medical and surgical care.
3Other reasons include endocrine, nutritional and metabolic diseases, certain infectious and parasitic diseases, mental and behavioural disorders, diseases of
the musculoskeletal system and connective tissue, symptoms, signs and abnormal clinical and laboratory ﬁndings, not elsewhere classiﬁed, and congenital
malformations, deformations, and chromosomal abnormalities.
occlusive disease, were generally similar between CaP pa-
tients, men with elevated PSA, and controls. The prevalence
of hypertension prior to the index date (5-6%) was lower
than in most population-based studies among older men
or CaP patients [25–29]. However, comparing our results
to the existing body of literature is particularly diﬃcult,
given the diﬀerences in study populations, study design, and
outcome deﬁnitions. Moreover, many studies presented the
prevalence data over multiple years, whereas in this study, we
examined the prevalence during a 12-month period prior to
CaPdiagnosisorﬁrstelevatedPSAresult,andincidenceafter
the index date.
When we examined the most frequently occurring com-
orbidities, the prevalence of urinary tract signs and symp-
toms remained similar over time for men with elevated PSA
(∼30%), despite an increase in alpha blocker use from 17%
during the 12 months prior to the elevated PSA results
to 32% during the 12 months after the elevated PSA re-
sults. For men with CaP, the prevalence of urinary tract
signs and symptoms was high (43%) during the prediag-
nostic period and dropped to 19% after diagnosis, likely
attributable to cancer treatment. Consistent with the study
design that controls must not have CaP, elevated PSA, and/or
any benign prostatic diseases, the prevalence of urinary tract
signs and symptoms and alphablocker use were low at 6–
8% over time among controls. Several medications, includ-
ingNSAIDs,nonopioidanalgesics,antiplateletdrugs,statins,
ACE inhibitors, and/or calcium channel blockers, were com-
monly used by these men, similarly across all four groups.
These results may serve as the background information for
better understanding drug-drug interactions during clinical
development.12 Journal of Cancer Epidemiology
This study showed that, in contrast to CaP patients, who
had over 2-fold higher all-cause mortality rate than their
matched controls, men with elevated PSA but no CaP had
a slightly lower mortality rate than their matched controls.
This may be explained by the relatively low PSA threshold
value we used to deﬁne an elevation in PSA level. It may
also be a reﬂection of the complexity of CaP screening using
PSA measurements and the subsequent eﬀect on CaP mor-
tality, demonstrated in several large randomized studies to
be controversial [18, 20, 30]. The cause of death analysis
was conducted among patients who consented to the linkage
between GPRD and death certiﬁcates. Among CaP, about
40% patients died of reasons other than CaP-speciﬁc death.
Diseases of circulatory and respiratory systems were impor-
tant competing risks for CaP patients and were typical causes
of death for all groups of men.
Wenoteseverallimitationsinourstudy.CaPpatientsand
menwithelevatedPSAwhocouldnotbematchedtocontrols
wereslightlyolderthanmatchedcases.Excludingunmatched
cases from the analysis could have introduced bias if they
diﬀered systematically from those who were matched. How-
ever, other baseline demographic factors including smoking
status and region of practice were similar between matched
and unmatched cases, arguing against substantial bias from
this source. Excluding men with BPH and/or prostatitis from
the controls could have magniﬁed case-control diﬀerences
for comorbidities or medications that are correlated with
BPHor prostatitis. The GPRDis a primary caredatabase and
relies on accurate upload of data from the member practices.
Data transfer from hospitals to the GPRD can be delayed or
missing if GPs do not code and enter the information when
they receive it from the hospital. We were unable to explore
prevalence and incidence of comorbidities and comedication
use by cancer stage and Gleason score because the GPRD
lacks these important details. The proﬁle of advanced CaP
patients and early-stage disease patients may well diﬀer with
respecttocomorbidities andespeciallymedication use,given
the indolent nature of the cancer.
Despite these limitations, this study has several strengths.
As previously shown [31], the GPRD provides a represen-
tative description of patients within the UK. It is a suitable
data source for this study, as it is proﬁcient at recording
comorbidities and medical care conducted by the GP in
primarycare.Furthermore,GPRDisanappropriatedatabase
especially for studying men with elevated PSA. Per National
InstituteforHealthandClinicalExcellence(NICE)guidance,
menwith elevated PSAareidentiﬁed initially in primary care
and receive a second test by the GP within 3 months after
the initial elevated PSA result. Patients then are referred to
a specialist, if the PSA level is elevated again. If CaP is not
diagnosed, patients will return to the care of the GP and be
followed within primary care.
6. Conclusions
This study provides population-based estimates on the oc-
currence of comorbidities and medication use among CaP
patients and men with elevated PSA but no CaP. Compared
withage-,region-andpractice-matchedcontrolswhohadno
CaPnorelevatedPSA,CaPpatientshadahigherincidenceof
urinary tract infection, impotence and breast disorder, and a
2.6-fold higher risk of all-cause mortality. Fewer diﬀerences
in comorbidities and medication use were noted when men
with elevated PSA but no CaP were compared to matched
men without elevated PSA nor CaP than were seen between
CaP patients and their matched controls. The mortality rates
were slightly lower for men with elevated PSA but no CaP
than for matched controls.
Cardiovascular events were similar between CaP patients
and their controls and between men with elevated PSA but
no CaP and their controls. At the time of diagnosis of
CaP or the ﬁrst occurrence of elevated PSA, many of the
most prevalent comorbidities and medications were consist-
entacrossgroupsandaretypicalofanoldermalepopulation.
As the presence of comorbid conditions and medications
places older patients at greater risk of adverse eﬀects from
certaininterventions,andcomorbiditymayinﬂuencescreen-
ing practice, treatment choice, quality of life, and survival,
these data in the real-world setting are broadly applicable
throughout the drug development cycle and subsequent pa-
tient management.
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